



University of Dundee

Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis

Chalmers, James D.; Metersky, Mark L.; Feliciano, Joseph; Fernandez, Carlos; Teper, Ariel; Maes, Andrea

Published in:
ERJ Open Research

DOI:
[10.1183/23120541.00695-2022](https://doi.org/10.1183/23120541.00695-2022)

Publication date:
2023

Licence:
CC BY

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Chalmers, J. D., Metersky, M. L., Feliciano, J., Fernandez, C., Teper, A., Maes, A., Hassan, M., & Chatterjee, A. (2023). Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis. *ERJ Open Research*, 9(3), Article 00695-2022. <https://doi.org/10.1183/23120541.00695-2022>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Benefit–risk assessment of brensocaticib for treatment of non-cystic fibrosis bronchiectasis

Copyright ©The authors 2023

This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.

Received: 10 Dec 2022

Accepted: 14 Feb 2023

To the Editor:

Bronchiectasis (also referred to as non-cystic fibrosis bronchiectasis [1]) is an inflammatory disease, characterised by permanently dilated bronchi, with chronic cough, sputum production and frequent exacerbations [2, 3]. Increased airway neutrophil elastase (NE) activity is associated with bronchiectasis disease progression and increased risk of pulmonary exacerbations [4, 5]. Brensocaticib is an investigational, small-molecule, orally bioavailable, selective, reversible dipeptidyl peptidase 1 inhibitor that blocks activation of neutrophil serine proteases including NE [1, 6, 7]. In the phase 2 randomised, double-blind, placebo-controlled WILLOW study (www.ClinicalTrials.gov identifier NCT03218917 [1]), patients received 10 mg brensocaticib (n=82), 25 mg brensocaticib (n=87) or placebo (n=87) once daily for 24 weeks [1]. The time to first exacerbation was prolonged with brensocaticib compared with placebo (adjusted hazard ratio (HR) 0.58, 95% CI 0.35–0.95 for the 10 mg dose; adjusted HR 0.62, 95% CI 0.38–0.99 for the 25 mg dose) and reductions in sputum NE were observed [1]. The most common serious adverse events (occurring in $\geq 3\%$ of patients) were infective exacerbation of bronchiectasis (6% for the 10 mg dose; 4% for the 25 mg dose; 11% with placebo) and pneumonia (0% for the 10 mg dose; 4% for the 25 mg dose; 4% with placebo [1]).

To facilitate interpretation of the brensocaticib clinical benefit–risk profile, a *post hoc* analysis of the WILLOW study was conducted to calculate the number needed to treat (NNT) and number needed to harm (NNH) for brensocaticib compared with placebo in patients with bronchiectasis. NNT and NNH analyses describe the number of patients that would need to be treated for one additional patient *versus* placebo to experience benefit or harm, respectively [8, 9].

The WILLOW study population included adults with computed tomography-confirmed bronchiectasis combined with a relevant clinical history and at least two exacerbations in the previous 12 months. Study details including full inclusion and exclusion criteria, study protocols and information on ethical approval have been published previously [1]. The proportion of patients with pulmonary exacerbations over 24 weeks was used for the NNT analysis and the proportion of patients with serious treatment-emergent adverse events (TEAEs) was used for the NNH analysis. Serious adverse events were defined as any untoward medical occurrence that, at any dose, result in death, are life-threatening, require hospitalisation or prolong existing hospitalisation, result in significant disability/incapacity or are congenital anomalies/birth defects. Since exacerbations were both an efficacy end-point and could be reported as an adverse event, an analysis of NNH was conducted after exclusion of exacerbations reported as serious TEAEs. NNT and NNH were calculated as $1/(f_{\text{brensocaticib}} - f_{\text{placebo}})$ with 95% CI, where $f_{\text{brensocaticib}}$ is the proportion of brensocaticib-treated patients with an exacerbation or serious TEAE, and f_{placebo} is the proportion of placebo-treated patients with an exacerbation or serious TEAE. Where the two-sided 95% CI for the risk difference included 0, the 95% CI included infinity. The upper bounds of the 95% CI for all NNH values were infinite (*i.e.* an infinite number of patients would be required to determine the NNH within the 95% CI). An infinite number of people being treated before harm is experienced would be the best possible scenario. Therefore, the worst-case scenario (a positive integer) for the lower bound of the NNH is reported. Negative NNH values suggest a favourable effect of brensocaticib treatment on safety parameters *versus* placebo [8].



Shareable abstract (@ERSpublications)

Brensocaticib is a novel anti-inflammatory therapy in development for bronchiectasis treatment. Phase 2 WILLOW trial data demonstrate a low number needed to treat and negative number needed to harm, suggesting a favourable benefit–risk profile. <https://bit.ly/3SbisW3>

Cite this article as: Chalmers JD, Metersky ML, Feliciano J, *et al.* Benefit–risk assessment of brensocaticib for treatment of non-cystic fibrosis bronchiectasis. *ERJ Open Res* 2023; 9: 00695-2022 [DOI: 10.1183/23120541.00695-2022].

The brensocatib-treated arms experienced a significantly lower proportion of exacerbations than the placebo-treated arm [1]; the NNTs for exacerbation prevention are presented in table 1. For patients in the brensocatib 10 mg (n=82) arm, the NNT was 6 (95% CI 3–50), due to the lower proportion of patients who experienced exacerbations with brensocatib than with placebo (31.7% *versus* 48.3%, p=0.03 [1]). In the 25 mg (n=87) arm the NNT was 7 (95% CI 3–197) with 33.3% of patients treated with brensocatib experiencing exacerbations (p=0.04) [1]. The NNT in the pooled (n=169) brensocatib treatment group was 6 (95% CI 4–33) with 32.5% experiencing exacerbations with brensocatib.

Fewer patients in the brensocatib 10 mg (n=81) arm experienced serious TEAEs over 24 weeks *versus* the placebo (n=85) group (13.6% *versus* 22.4%, p=0.14), and significantly fewer in the brensocatib 25 mg (n=89) arm (11.2%, p=0.049 [1]). The NNH values for the proportion of patients with serious TEAEs, including exacerbations, are presented in table 1. The NNH for the brensocatib 10 mg arm was –11 (95% CI | >5), and for the brensocatib 25 mg arm the NNH was –9 (95% CI | >5). The NNH in the pooled (n=170) brensocatib group was –10 (95% CI | >5), with 12.4% of patients treated with brensocatib experiencing serious TEAEs *versus* 22.4% in the placebo group.

The reduced risk of serious TEAEs was maintained in the results of the NNH analysis excluding exacerbations as a harm. The NNH values for the proportion of patients with serious TEAEs, excluding exacerbations, are presented in table 1. The NNH value excluding exacerbations for the brensocatib 10 mg arm was –55 (95% CI | >9). The NNH value excluding exacerbations in the 25 mg arm was –25 (95% CI | >8). p-values for serious TEAEs excluding exacerbations in the 10 mg and 25 mg arms *versus* placebo were 0.19 and 0.79, respectively [1]. In the pooled (n=170) brensocatib group, the NNH value excluding exacerbations was –34 (95% CI | >9), and 10.0% of patients treated with brensocatib experienced serious TEAEs (excluding exacerbations) *versus* 12.9% of patients receiving placebo.

Exacerbations are critical events in the natural history of bronchiectasis [3]. Frequent exacerbations are associated with a deterioration in quality of life, an increased risk of hospital admission, increased loss of lung function, and mortality [3, 10]. Therefore, an intervention that can prevent patients from experiencing exacerbations over time is of potential clinical importance. As brensocatib is a novel treatment, data on the relative efficacy and safety are important. Clinicians may use NNT and NNH values to better assess the

TABLE 1 Numbers needed to treat (NNTs) for exacerbation prevention and numbers needed to harm (NNHs) for serious treatment-emergent adverse events (TEAEs), including and excluding exacerbations

	Patients	Brensocatib	Placebo	NNT (95% CI)	NNH (95% CI) ^{*,†}
NNTs for exacerbation prevention (end-point: number with exacerbations[‡])					
Patients			87		
Brensocatib 10 mg [§]	82	26 (31.7)	42 (48.3)	6 (3–50)	
Brensocatib 25 mg [§]	87	29 (33.3)	42 (48.3)	7 (3–197)	
Brensocatib pooled	169	55 (32.5)	42 (48.3)	6 (4–33)	
NNHs including exacerbations (end-point: number with serious TEAEs[‡])					
Patients			85		¶¶,++
Brensocatib 10 mg [‡]	81	11 (13.6)	19 (22.4)		–11 (>5)
Brensocatib 25 mg ^{###}	89	10 (11.2)	19 (22.4)		–9 (>5)
Brensocatib pooled	170	21 (12.4)	19 (22.4)		–10 (>5)
NNHs excluding exacerbations (end-point: number with serious TEAEs[‡] (excluding exacerbations))					
Patients			85		++,\$\$
Brensocatib 10 mg [‡]	81	9 (11.1)	11 (12.9)		–55 (>9)
Brensocatib 25 mg [‡]	89	8 (9.0)	11 (12.9)		–25 (>8)
Brensocatib pooled	170	17 (10.0)	11 (12.9)		–34 (>9)

Data are presented as n or n (%), unless otherwise stated. [‡]: 95% CI for NNH analyses are reported as absolute values; [¶]: the two-sided 95% CI of risk difference included 0; therefore, the noncontinuous 95% CI generated indicates that the upper bound of the 95% CI for NNH is infinite (*i.e.* an infinite number of patients would be required to show any harm within the 95% CI); [‡]: over 24 weeks; [§]: p<0.05 *versus* placebo for proportion of patients experiencing exacerbations [1]; [‡]: p>0.05 *versus* placebo for proportion of patients experiencing serious TEAEs [1]; ^{###}: p<0.05 *versus* placebo for proportion of patients experiencing serious TEAEs [1]; ^{¶¶}: the worst case scenario of lower bound of NNH (including exacerbations) was 5; ⁺⁺: negative NNH values suggest a favourable effect of brensocatib treatment on safety parameters *versus* placebo; ^{\$\$}: the worst case scenarios of lower bound of NNH (excluding exacerbations) were 9 for brensocatib 10 mg and the brensocatib pooled groups, and 8 for brensocatib 25 mg.

potential benefit–risk profile of an intervention and its possible impact on clinical practice [8, 9]. Here, potential benefit of brensocatib *versus* placebo is suggested by the NNT results, as NNT values of <10 indicate that a treatment has substantial benefit [8].

A potential limitation is that this was a *post hoc* analysis of phase 2 trial results. While there is always a possibility that a phase 3 trial may have different results from its associated phase 2 trial, the findings in this analysis indicate a potential clinical importance, which the ongoing phase 3 ASPEN study (www.ClinicalTrials.gov identifier NCT04594369) aims to substantiate.

Furthermore, in this analysis, the 10 mg brensocatib dose had a lower NNT and more negative NNH than the 25 mg dose, although these results may have been expected of the higher dose. However, it should be noted that this study was not designed to differentiate efficacy by dose.

In conclusion, the analysis discussed here adds to the findings of the WILLOW study. The WILLOW study demonstrated that brensocatib prolonged the time to the first exacerbation and led to a lower risk of exacerbations compared with placebo in patients with bronchiectasis [1]. In the present analysis, the low NNT and negative NNH suggest a potential positive benefit–risk profile of brensocatib. Collectively, these results may indicate that brensocatib could be an important addition to the treatment of patients with bronchiectasis. The phase 3 ASPEN study is ongoing and aims to confirm these findings.

James D. Chalmers¹, Mark L. Metersky², Joseph Feliciano³, Carlos Fernandez³, Ariel Teper³, Andrea Maes³, Mariam Hassan³ and Anjan Chatterjee³

¹Ninewells Hospital and Medical School, University of Dundee, Dundee, UK. ²University of Connecticut School of Medicine, Farmington, CT, USA. ³Insmad Incorporated, Bridgewater, NJ, USA.

Corresponding author: James D. Chalmers (jchalmers@dundee.ac.uk)

Provenance: Submitted article, peer reviewed.

Acknowledgements: We thank the patients and their families for their support and participation, and the study investigators, study coordinators and support staff across all sites. Medical writing and editorial assistance were provided by Sari Cumming (Articulate Science, Manchester, UK), funded by Insmad Incorporated.

Support statement: This study was funded by Insmad Incorporated. Funding information for this article has been deposited with the Crossref Funder Registry.

Conflict of interest: J.D. Chalmers has received grants and personal fees from AstraZeneca, Boehringer Ingelheim, GSK, Zambon and Insmad Incorporated; a grant from Gilead; and personal fees from Novartis and Chiesi within the past 24 months. He is an associate editor of this journal. M.L. Metersky has received consulting fees from Insmad Incorporated, Boehringer Ingelheim, California Institute for Biomedical Research and Zambon; and his institution has received clinical trial support from Insmad Incorporated. J. Feliciano, C. Fernandez, A. Teper, A. Maes, M. Hassan and A. Chatterjee are employed by Insmad Incorporated.

References

- 1 Chalmers JD, Haworth CS, Metersky ML, *et al.* Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. *N Engl J Med* 2020; 383: 2127–2137.
- 2 Barker AF. Bronchiectasis. *N Engl J Med* 2002; 346: 1383–1393.
- 3 Chalmers JD, Aliberti S, Filonenko A, *et al.* Characterization of the “frequent exacerbator phenotype” in bronchiectasis. *Am J Respir Crit Care Med* 2018; 197: 1410–1420.
- 4 Keir HR, Shoemark A, Dicker AJ, *et al.* Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. *Lancet Respir Med* 2021; 9: 873–884.
- 5 Chalmers JD, Moffitt KL, Suarez-Cuartin G, *et al.* Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. *Am J Respir Crit Care Med* 2017; 195: 1384–1393.
- 6 Palmér R, Mäenpää J, Jauhiainen A, *et al.* Dipeptidyl peptidase 1 inhibitor AZD7986 induces a sustained, exposure-dependent reduction in neutrophil elastase activity in healthy subjects. *Clin Pharmacol Ther* 2018; 104: 1155–1164.
- 7 Doyle K, Lönn H, Käck H, *et al.* Discovery of second generation reversible covalent DPP1 inhibitors leading to an oxazepane amidoacetonitrile based clinical candidate (AZD7986). *J Med Chem* 2016; 59: 9457–9472.

- 8 Arnaud A, Suthoff E, Stenson K, *et al.* Number needed to treat and number needed to harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder. *J Affect Disord* 2021; 285: 112–119.
- 9 Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. *Int J Clin Pract* 2013; 67: 407–411.
- 10 Brill SE, Patel AR, Singh R, *et al.* Lung function, symptoms and inflammation during exacerbations of non-cystic fibrosis bronchiectasis: a prospective observational cohort study. *Respir Res* 2015; 16: 16.